Evidence map›Paper›PMID 40624553›Full record

ReviewChinese medicine2025

Herb-drug interactions in oncology: pharmacodynamic/pharmacokinetic mechanisms and risk prediction.

Xiaoyan Duan, Xiaoyu Fan, Haiyan Jiang, Jie Li, Xue Shen, Zeao Xu, Ziqi Zhou, Jia Xu, Chongze Chen, Hongtao Jin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Evaluation of Web-based Information on Phytotherapy for Cancer Patients: A Quality and Readability Analysis.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026
    Article
  3. Plant-Derived Bioactive Compounds and Their Therapeutic Potential in Cancer.International journal of molecular sciences · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoyan DuanNew Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Xiaoyu FanNew Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Haiyan JiangNew Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Jie LiNew Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Xue ShenFaculty of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang, 110016, Liaoning, China.
Zeao XuCollege of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, 110016, Liaoning, China.
Ziqi ZhouNew Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
Jia XuDepartment of Dermatology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, China. doctorxujia@163.com.ORCID http://orcid.org/0000-0001-9884-2772
Chongze ChenDepartment of Pharmacy, Fuzhou Changle People's District Hospital, Fuzhou, 350299, Fujian, China. chongze@126.com.ORCID http://orcid.org/0009-0001-3423-5751
Hongtao JinNew Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China. jinhongtao@imm.ac.cn.ORCID http://orcid.org/0000-0002-0638-707X

Funding

National Natural Science Foundation of China 82074104National Natural Science Foundation of China 82474169
6 · The paper itself

Abstract

The prevalence of herbal medicines has gained widespread, particularly among cancer patients seeking adjunctive therapies. Co-administered with anticancer drugs (ACDs) frequently, herbal medicines result in increasing cases of herb-drug interactions (HDIs), following the serious clinical consequences. While herbal medicines pose negative impacts, such as limiting efficacy and increasing toxicity of ACDs, they also offer potential benefits, including enhancing bioavailability, reducing adverse reactions, and reversing tumor drug resistance. This review is the first to systematically characterize HDI molecular mechanisms at both pharmacodynamic (PD) and pharmacokinetic (PK) levels, elucidating how herbal medicines modulate ACDs efficacy and safety through antagonism/synergy/detoxification target, metabolic enzymes, and transporters. In particular, emerging risk prediction methodologies are proposed to assess the clinical occurrence of potential PD/PK-mediated HDIs. We provide a novel insight for promoting the mechanism study of HDIs, facilitating the safe and effective integration of herbal medicines into cancer treatment.

Indexed as

CancerHerbal medicinesHerb-drug interactionsPharmacodynamicPharmacokineticRisk prediction

Identifiers

PMID40624553
PMCPMC12232703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.